Aussie court tosses Lipitor suit against Pfizer; Novartis nabs FDA approval for multiple myeloma med;

> Pfizer's ($PFE) strategy of offering steep Lipitor rebates as the drug's patent neared expiration didn't constitute anticompetitive conduct, an Australian judge said, tossing a lawsuit filed by the Australian Competition and Consumer Commission. Report (sub. req.)

> Novartis ($NVS) won FDA approval for its multiple myeloma drug Farydak, as a third line treatment. Report

> The global cancer drug market is expected to hit $111 billion by 2020, new market research shows. Report

> Hospira ($HSP) and Celltrion launched their biosimilar versions of Remicade in Europe, where the brand earned €2 billion last year. Report (reg. req.)

And Finally... Preventive treatment with an HIV drug reduced infection by 86% in gay men at high risk of contracting the disease. Report

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.